Table 2.

Baseline characteristics

	Apixaban (n = 128)	Warfarin (n = 733)	P
Age, mean (±SD), y	74 (±14)	67 (±15)	<.01
Female, n (%)	74 (57.8)	384 (52.4)	.256
Comorbidities, n (%)
Heart failure	68 (53.1)	262 (35.7)	<.01
Atrial fibrillation	81 (63.3)	216 (29.5)	<.01
DVT/PE	21 (14.4)	235 (32.1)	<.01
Hypertension	57 (44.5)	387 (52.8)	.086
History of stroke	16 (12.5)	92 (12.6)	1
Myocardial infarction	27 (21.1)	167 (22.8)	.73
History of bleeding	8 (6.3)	44 (6)	.84
CABG	13 (10.2)	42 (4.7)	.08
Diabetes	44 (34.4)	273 (37.2)	.55
Hyperlipidemia	57 (44.5)	218 (29.7)	<.01
Peripheral artery disease	15 (11.7)	58 (7.9)	.17
History of smoking	32 (25)	120 (16.4)	.02
History of falls	5 (3.9)	18 (2.5)	.37
Hypercoagulable	0 (0.0)	9 (1.2)	.37
Hemodialysis	21 (16.4)	118 (16.1)	.90
Renal transplant	0 (0)	18 (2.5)	.09
Liver disease	13 (10.2)	56 (7.6)	.38
Laboratory values, median (IQR)
Study CrCl,  mL/min	18.7 (12.3,22.6)	14.8 (10.1,19.5)	<.01
Baseline INR	1.2 (1.1,1.5)	1.1 (1.1,1.2)	.03
Baseline hemoglobin, g/dL	10.2 (9.1,11.8)	9.7 (8.5,11)	<.01
Anticoagulation indication, n (%)
Atrial fibrillation/flutter	71 (55.5)	226 (30.8)	<.01
History of atrial fibrillation	26 (20.3)	32 (4.4)	<.01
Acute VTE	20 (15.6)	350 (47.7)	<.01
Chronic VTE	3 (2.3)	7 (1)	.19
Valve replacement	0 (0)	16 (2.2)	.09
Cardiac thrombus	2 (1.6)	17 (2.3)	.55
Other	0 (0)	40 (5.5)	.01
Multiple	6 (4.7)	45 (6.1)	.48
Concomitant agents, n (%)
Aspirin	82 (64.1)	473 (64.5)	.92
Clopidogrel	9 (7)	86 (11.7)	.12
Cilostazol	7 (5.5)	20 (2.7)	.10
Ticagrelor	1 (0.8)	3 (0.4)	.48
Apixaban dosing, n (%)
2.5 mg twice daily	73 (57)
5 mg twice daily	55 (43)
Incorrect dosing	21 (16.4)

aPTT, activated partial thromboplastin time; CABG, coronary artery bypass graft; INR, international normalized ratio; TIA, transient ischemic stroke.